IGLV9-49: A Potential Drug Target (G28773)

Target Name: IGLV9-49

NCBI ID: G28773

IGLV9-49

Other Name(s): V5-2 | IGLV949 | Immunoglobulin lambda variable 9-49 | immunoglobulin lambda variable 9-49

IGLV9-49: A Potential Drug Target

IGLV9-49 (V5-2) is a protein that is expressed in various tissues of the human body, including the brain, lungs, heart, kidneys, and intestines. It is a member of the intergenital lymphoid (IGL) family, which includes several proteins that play important roles in the immune system.

One of the unique features of IGLV9-49 is its structure. It is a type of transmembrane protein that consists of an extracellular region, a transmembrane region, and an intracellular region. The extracellular region includes several well- conserved domains that are involved in the protein's ability to interact with other molecules in the body. The transmembrane region is responsible for the protein's ability to span the cell membrane and interact with intracellular signaling molecules. The intracellular region includes several unique domains that are involved in the protein's ability to interact with other proteins inside the cell.

IGLV9-49 has been shown to play a number of important roles in various biological processes in the body. For example, it is involved in the regulation of immune responses, and has been shown to play a role in the development of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. It is also involved in the regulation of cell signaling pathways, and has been shown to play a role in the regulation of cell proliferation and differentiation.

In addition to its potential role in the immune system, IGLV9-49 has also been shown to play a number of important roles in the regulation of other biological processes in the body. For example, it is involved in the regulation of cell migration, and has been shown to play a role in the development of cancer. It is also involved in the regulation of cell signaling pathways, and has been shown to play a role in the regulation of cell proliferation and differentiation.

With its unique structure and variety of functions, IGLV9-49 is an attractive drug target for researchers to study. Studies have shown that IGLV9-49 can be effectively targeted with small molecules, antibodies, and other therapeutic agents. For example, researchers have been shown to be able to significantly reduce the expression of IGLV9-49 in cancer cells using small molecules such as inhibitors of the protein's signaling pathways. Similarly, researchers have been able to significantly increase the expression of IGLV9-49 in immune cells using antibodies that recognize and target the protein.

In conclusion, IGLV9-49 is a protein that has the potential to be a drug target or biomarker. Its unique structure and variety of functions make it an attractive target for researchers to study, and its potential as a drug or biomarker makes it a promising area of research for the development of new treatments for a variety of diseases.

Protein Name: Immunoglobulin Lambda Variable 9-49

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV9-49 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV9-49 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets